Development of subtype-selective oestrogen receptor-based therapeutics. - sprookjes - yvandenbroek - TriplyDB

Development of subtype-selective oestrogen receptor-based therapeutics.

Development of subtype-selective oestrogen receptor-based therapeutics.

http://www.wikidata.org/entity/Q34216817

about

Steroid hormone receptors and prostate cancer: role of structural dynamics in therapeutic targeting Insights into rapid modulation of neuroplasticity by brain estrogens Ubiquitin-fold modifier 1 acts as a positive regulator of breast cancer Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects Prediction of selective estrogen receptor beta agonist using open data and machine learning approach Oestrogen increases haematopoietic stem-cell self-renewal in females and during pregnancy.Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of Alzheimer's disease.Mutation of the palmitoylation site of estrogen receptor α in vivo reveals tissue-specific roles for membrane versus nuclear actions.In search of novel drug target sites on estrogen receptors using RNA aptamers.Estrogen-Related Factors in the Frontal Lobe of Alzheimer's Disease Patients and Importance of Body Mass Index.An alternative conformation of ERβ bound to estradiol reveals H12 in a stable antagonist position Selective estrogen receptor modulators: tissue specificity and clinical utility.Emerging medication for the treatment of male hypogonadism.Sexual dimorphic regulation of body weight dynamics and adipose tissue lipolysis Selective ligands of estrogen receptor β discovered using pharmacophore mapping and structure-based virtual screening.Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential.Antidiabetic actions of an estrogen receptor β selective agonist.Noncanonical mechanisms to regulate nuclear receptor signaling.Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity.Estrogen receptor ligands: a patent review update.Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism 2,3-cis-2R,3R-(-)-epiafzelechin-3-O-p-coumarate, a novel flavan-3-ol isolated from Fallopia convolvulus seed, is an estrogen receptor agonist in human cell lines.Tumour nuclear oestrogen receptor beta 1 correlates inversely with parathyroid tumour weight.Salinomycin enhances doxorubicin-induced cytotoxicity in multidrug resistant MCF-7/MDR human breast cancer cells via decreased efflux of doxorubicin.Estrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines.17β-estradiol signaling and regulation of Sertoli cell function International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators Controllable drug uptake and nongenomic response through estrogen-anchored cyclodextrin drug complex Estradiol Receptors Regulate Differential Connexin 43 Expression in F98 and C6 Glioma Cell Lines.Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD).PES1 promotes breast cancer by differentially regulating ERα and ERβ.Oestrogen receptor alpha in pulmonary hypertension.Synthesis and biological evaluation of two agents for imaging estrogen receptor β by positron emission tomography: challenges in PET imaging of a low abundance target.Estrogen receptor β in Alzheimer's disease: From mechanisms to therapeutics.Re-adopting classical nuclear receptors by cholesterol metabolites.Thiophene-core estrogen receptor ligands having superagonist activity.Interaction of 14-3-3 proteins with the estrogen receptor alpha F domain provides a drug target interface.ERβ-dependent effects on uterine endothelial cells are cell specific and mediated via Sp1.

P2860

Q26745907-7C88B82B-85F6-450A-AC05-591BE0F61E9B Q26863428-2CE19C5A-B614-490C-BC8C-02B90FE89866 Q27016134-39AA3F97-B8C1-4682-989A-0F8BB3F59F53 Q27683572-6B944FF1-8A42-450D-9F79-A3AB218A1C21 Q28078465-2F134EDB-EA2B-4844-9DFA-62A6D6B911DD Q28087001-8BBB580F-2A47-4C4A-B662-3BCEC2DC69BA Q28595946-7FB6B1EA-A3E8-4742-852E-40DC0317A429 Q30411786-EDCE8699-FBCD-4ADA-8D4F-95F452C11344 Q30560110-07138580-76C7-466F-976B-6C949C21DBB2 Q30565938-75110FA1-E7B3-40A4-92D3-B7FC16E7D14B Q33632085-0681FFD3-B283-41F5-9F46-A145D9DECABC Q33677902-D16915A1-F4D0-40E1-B457-182A4EC51F15 Q33799630-62AF56F1-B35F-4F6F-9883-B1E5C3A11354 Q34134828-F71261D6-80DC-48FA-A27D-CA8DA8A15B3A Q34276286-93292B13-A05A-475C-862F-C668F1DD587E Q34291294-A96C1843-AC33-4DC4-AAF0-48A6A92B4BB4 Q34295026-B13C6828-ABBC-4965-B98B-2E51084FB653 Q34315419-B1417376-4D85-4A84-BB28-E00C8A003CB4 Q34324370-13D7D664-0ED7-42CE-AB41-1DCD6EA305F1 Q34338685-A38589FB-A007-4895-878A-4A0F760CB928 Q34340354-B779ACBA-1279-4F40-B618-1F41149C19E2 Q34347152-9E7DEF6D-7076-4E1F-AEA4-2A8689C6AF81 Q34382405-8B974848-EDA9-49A7-A145-5E85E0721402 Q34773658-C9563506-B810-4000-8AC8-E77E4657E647 Q35153386-2A3D41AE-D32F-4164-AC59-CAF038818DE7 Q35609552-B15A820C-18AC-4C2B-95F6-3C814BE54359 Q35725686-18074551-3F39-41FC-B809-D3D7F964E365 Q35733196-CDB72978-DEB9-4210-B798-BD1BE44DF8F1 Q35795751-69002C2B-1D48-445A-8481-4777BBC80E89 Q35914934-98978CDF-966D-4270-9669-50211644E5EE Q35937315-41CA9A90-BCC0-46B4-A8B1-CFD701A932FD Q36103515-36E1BB42-0D46-44D4-BACA-43C6A13BB91F Q36129096-379C93A4-F3E7-4A9E-BD59-1C0A8606CD38 Q36191733-108E0A80-3172-438A-926F-8DED5117C1BA Q36301166-E0642B1D-B386-4385-8246-A6EDCD7C7882 Q36322578-DBD48FC9-B707-4673-89F0-21E648AEBEFA Q36494078-9746BD5B-34A8-40FA-A37E-D266EB12141C Q36883747-40116141-0CD2-45E6-A33C-9338C4F6B559 Q36895738-3D9B5CC4-51B4-4616-89AA-F479B0AEB4BD Q37109078-CC154852-3577-4359-AD80-03785B87B329

P2860

Development of subtype-selective oestrogen receptor-based therapeutics.

http://www.wikidata.org/entity/Q34216817

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Development of subtype-selective oestrogen receptor-based therapeutics.

@ast

Development of subtype-selective oestrogen receptor-based therapeutics.

@en

Development of subtype-selective oestrogen receptor-based therapeutics.

@nl

type

label

Development of subtype-selective oestrogen receptor-based therapeutics.

@ast

Development of subtype-selective oestrogen receptor-based therapeutics.

@en

Development of subtype-selective oestrogen receptor-based therapeutics.

@nl

prefLabel

Development of subtype-selective oestrogen receptor-based therapeutics.

@ast

Development of subtype-selective oestrogen receptor-based therapeutics.

@en

Development of subtype-selective oestrogen receptor-based therapeutics.

@nl

P1433

Q34216817-DF388337-9E59-4D9B-9871-96718B38F9C0

P1476

Q34216817-82FFF18E-86D6-4269-BC00-05D214BCF8D7

P2093

Q34216817-6861219D-6D32-4850-8CA7-913EA056CB0B

Q34216817-DE15D3F6-BB05-4985-A6E4-B3B9D0E72A67

P2860

Q34216817-023E0212-112C-4415-B45B-033FBCE3BB30

Q34216817-0353F6B2-087E-4F68-AEFA-7AD2A2120E25

Q34216817-03C0B562-59F0-4E3C-88ED-5F8185B4E880

Q34216817-0609A133-A8C3-4789-9D9F-5508A5B6E3C7

Q34216817-061C110C-8ADF-4D23-813F-CDC351001352

Q34216817-074CE96F-9CA0-4CFA-9E64-59A04098CB64

Q34216817-084062ED-3D62-4D29-BAA2-60DDBDE78592

Q34216817-09425285-043E-4C41-96C5-9BE881802896

Q34216817-0E848D42-6C8D-4E7E-91A5-F7FEF61AE036

Q34216817-11E279E5-FB83-4560-846F-1A21F22368E3

P2888

Q34216817-D70C948E-C465-490E-AD26-A8E362FDC67F

P304

Q34216817-0FCE7BCD-4580-4208-9075-4158D37B2281

P31

Q34216817-9CFD701D-F579-4A14-85B8-978CC3480472

P356

Q34216817-5465DE7E-6D25-46AD-8A34-3165438E98AC

P433

Q34216817-1062C0CB-5D22-4CB4-AFEF-6A70A1FD572D

P478

Q34216817-9D21903C-7F09-4449-A6F9-A12CAFE90C31

P50

Q34216817-824978B5-C4D3-45C3-8A7B-D4FC38CC1DDC

P577

Q34216817-8A699838-7E3D-4D43-AB88-31A38326BF64

P698

Q34216817-38F8A526-3C54-4C15-8E8C-6FFBAD4D9B0B

P356

P1433

Nature Reviews Drug Discovery

P1476

Development of subtype-selective oestrogen receptor-based therapeutics

@en

P2093

Jan-Åke Gustafsson

http://www.w3.org/2001/XMLSchema#string

Stefan Nilsson

http://www.w3.org/2001/XMLSchema#string

P2860

Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists

Estrogen receptor beta-selective agonists stimulate calcium oscillations in human and mouse embryonic stem cell-derived neurons

Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha

Regulation of specific target genes and biological responses by estrogen receptor subtype agonists

Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes

Estrogen Receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding

Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist

Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligand treatment

Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist

Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 5: Combined A- and C-ring structure-activity relationship studies

P2888

P304

778-792

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRD3551

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21921919

http://www.w3.org/2001/XMLSchema#string